RxDoctor Payments DataLook up a doctor →

Stephen South, MD

Endocrinology, Diabetes & Metabolism · Greensboro, NCNPI 1043237472

Payments from drug & device makers

$624,185in general payments, 2019–2025

Across 1,465 payments — averaging $426.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$514K
  • Boehringer Ingelheim$37K
  • Johnson & Johnson$29K
  • Amgen$18K
  • Madrigal Pharmaceuticals$11K
  • Valeritas, Inc.$3K
  • plus $11K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC760$514,345
Boehringer Ingelheim85$36,762
Johnson & Johnson53$28,992
Amgen(2 entities)74$18,321
Madrigal Pharmaceuticals14$10,999
Valeritas, Inc.7$3,290
Novo Nordisk89$1,382
Cequr Corporation5$968
AbbVie(2 entities)49$925
Bayer20$718
AstraZeneca20$666
Medtronic(2 entities)13$635
Intra-sana Laboratories5$598
Abbott25$500
Sanofi-aventis U.S. LLC20$499
GSK15$429
Esperion Therapeutics, Inc.11$390
Radius Health, Inc.16$294
Astellas Pharma US Inc19$258
Dexcom, Inc.9$258
Novartis16$256
Amarin Pharma, Inc.7$193
Exact Sciences5$173
Otsuka America Pharmaceutical, Inc.6$147
Mannkind Corporation7$142
BETA Bionics, Inc.2$137
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC9$132
Actelion Pharmaceuticals US, Inc.2$120
Lifescan, Inc.7$106
Pfizer8$106
Tandem Diabetes Care, Inc.2$97
Amneal Pharmaceuticals LLC6$90
Merck7$89
Biohaven Pharmaceuticals, Inc.6$89
Sunovion Pharmaceuticals Inc.6$86
Takeda Pharmaceuticals U.S.A., Inc.6$77
Biohaven Pharmaceutical Holding Company Ltd.4$77
Sumitomo Pharma America, Inc.4$67
Neurocrine Biosciences, Inc.3$66
Sanofi Pasteur Inc.3$59
Xeris Pharmaceuticals, Inc.4$55
Regeneron Healthcare Solutions, Inc.3$51
Insulet Corporation3$47
E.r. Squibb & Sons, L.L.C.3$45
Shield Therapeutics Inc3$45
Daiichi Sankyo Inc.2$44
Mylan Specialty L.p.2$42
Ironwood Pharmaceuticals, Inc3$34
Genentech USA, Inc.2$31
IBSA Pharma Inc.2$29
Sequel Med Tech, LLC1$22
Viatris Specialty LLC1$21
Verity Pharmaceuticals Inc.1$20
ARS Pharmaceuticals Operations, Inc.1$20
Idorsia Pharmaceuticals US Inc1$19
Irhythm Technologies, Inc.1$19
Corcept Therapeutics1$19
Nevro Corp.1$18
Antares Pharma, Inc.1$17
Shire North American Group Inc1$17

How this compares

$624,185 in reported general payments places this provider in the 90th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.

See all endocrinology, diabetes & metabolism providers in North Carolina →

Medicare billing

Part B allowed, 2024
$108,395
Medicare patients
198
Services billed
2,529

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Greensboro

See the full list for North Carolina →

Where these figures come from

Is this you, or does something look wrong? →